| scholarly article | Q13442814 |
| P50 | author | José M. Tenías | Q47502869 |
| P2093 | author name string | Alfredo J Lucendo | |
| Sonia González-Castillo | |||
| Germán López-Larramona | |||
| P2860 | cites work | Glucocorticosteroids for primary biliary cirrhosis | Q24244255 |
| Guidelines on the management of osteoporosis associated with chronic liver disease | Q24685899 | ||
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group | Q28239579 | ||
| Hepatic osteodystrophy and liver cirrhosis | Q33764798 | ||
| Hepatic osteodystrophy. | Q34109988 | ||
| Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice | Q34223451 | ||
| Osteoporosis and skeletal fractures in chronic liver disease | Q34391773 | ||
| Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection | Q35011138 | ||
| Osteoporosis in liver diseases and after liver transplantation | Q35134421 | ||
| AGA technical review on osteoporosis in hepatic disorders. | Q35209520 | ||
| Effect of Chronic Alcohol Ingestion on Bone Mineral Density in Males without Liver Cirrhosis | Q35937162 | ||
| Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis | Q36044995 | ||
| Bad to the bone: the effects of liver diseases on bone. | Q36078017 | ||
| Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy | Q36119487 | ||
| Evaluation and management of osteoporosis in liver disease | Q36278269 | ||
| Liver disease and osteoporosis. | Q36506087 | ||
| Vitamin D replacement for cirrhosis-related bone disease | Q36666317 | ||
| Is alcohol an osteoporosis-inducing agent for young and middle-aged women? | Q36766361 | ||
| Bone disorders in chronic liver disease | Q36948504 | ||
| Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment | Q37154329 | ||
| Bone mineral density and disorders of mineral metabolism in chronic liver disease | Q37275718 | ||
| Cholestasis and metabolic bone disease - a clinical review | Q37322123 | ||
| Current understanding of osteoporosis associated with liver disease | Q37625814 | ||
| Bone Disorders in Chronic Liver Diseases | Q37811999 | ||
| Bone disorders in patients with chronic liver disease awaiting liver transplantation. | Q38484693 | ||
| Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis | Q43246219 | ||
| Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. | Q43332166 | ||
| Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis | Q43589038 | ||
| Assessment of bone metabolism and mineral density in chronic viral hepatitis | Q43767047 | ||
| Statement on results of the HERS II trial on hormone replacement therapy | Q43903081 | ||
| Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. | Q44025886 | ||
| Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis | Q44627887 | ||
| Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study | Q45255372 | ||
| Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. | Q46215836 | ||
| Primary biliary cirrhosis and osteoporosis: a case-control study | Q46351576 | ||
| Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. | Q46608575 | ||
| Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study | Q46611597 | ||
| Prevalence of vitamin D deficiency in chronic liver disease | Q46631954 | ||
| Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial | Q46714065 | ||
| Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial | Q46954457 | ||
| Etiopathogenesis of hepatic osteodystrophy in Wistar rats with cholestatic liver disease. | Q47855166 | ||
| Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. | Q50636283 | ||
| Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. | Q50684179 | ||
| Bone mineral density before and after OLT: long-term follow-up and predictive factors. | Q50787854 | ||
| Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. | Q50970251 | ||
| Osteoporosis in chronic liver disease: a case-control study. | Q51623988 | ||
| Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. | Q51650453 | ||
| Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. | Q51802919 | ||
| Human Parathyroid Hormone 1–34 Prevents Bone Loss in Experimental Biliary Cirrhosis in Rats | Q53529162 | ||
| The RANKL/OPG system and bone mineral density in patients with chronic liver disease. | Q53658379 | ||
| Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. | Q55035486 | ||
| Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism | Q58868283 | ||
| Factors influencing the development of metabolic bone disease in primary biliary cirrhosis | Q68573003 | ||
| Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids | Q68903834 | ||
| Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? | Q69951457 | ||
| The effect of transdermal oestrogen on bone, calcium-regulating hormones and liver in postmenopausal women | Q70354327 | ||
| Hormone replacement therapy in women with liver disease | Q71956992 | ||
| Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis | Q72144895 | ||
| Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis | Q72164989 | ||
| Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? | Q72511247 | ||
| Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment | Q72688424 | ||
| Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis | Q72948324 | ||
| Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study | Q73130933 | ||
| High serum osteoprotegerin and low RANKL in primary biliary cirrhosis | Q73187923 | ||
| Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload | Q73687008 | ||
| Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease | Q74629416 | ||
| Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry | Q77150135 | ||
| Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years | Q78196764 | ||
| Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients | Q79325380 | ||
| Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia | Q79903139 | ||
| Bone mineral density among cirrhotic patients awaiting liver transplantation | Q79988065 | ||
| Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis | Q80042381 | ||
| P433 | issue | 12 | |
| P921 | main subject | chronic liver disease | Q5113984 |
| P304 | page(s) | 300-307 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | World Journal of Hepatology | Q27723328 |
| P1476 | title | Hepatic osteodystrophy: An important matter for consideration in chronic liver disease | |
| P478 | volume | 3 |
| Q37328367 | Association Between Chronic Hepatitis B Virus Infection and Risk of Osteoporosis: A Nationwide Population-Based Study |
| Q99617150 | Association of serum osteoprotegerin with severity of chronic liver disease in female patients: A potential biomarker |
| Q91656265 | Bone disease in cirrhosis |
| Q38849637 | Bone health and vitamin D status in alcoholic liver disease |
| Q35173677 | Bone mineralization in children with Wilson's disease |
| Q38880727 | Cirrhosis-related musculoskeletal disease: radiological review |
| Q28069053 | Diagnosis and Management of Cirrhosis-Related Osteoporosis |
| Q38238274 | Elevated Alkaline Phosphatase in Infants With Parenteral Nutrition-Associated Liver Disease Reflects Bone Rather Than Liver Disease |
| Q64998522 | Hepatic Osteodystrophy-Molecular Mechanisms Proposed to Favor Its Development. |
| Q27004571 | Hepatic osteodystrophy |
| Q38044761 | Immunomodulating options for liver transplant patients |
| Q34942815 | Liver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes |
| Q38911526 | Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys. |
| Q33824596 | Modeling hepatic osteodystrophy in Abcb4 deficient mice |
| Q35791650 | Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti-γ-Glutamyl Transpeptidase Antibody |
| Q26746935 | Osteoporosis in liver disease: pathogenesis and management |
| Q37370997 | Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats |
| Q36789908 | Physiologic frailty and fragility fracture in HIV-infected male veterans |
| Q40043672 | Reduced serum IGF-1 associated with hepatic osteodystrophy is a main determinant of low cortical but not trabecular bone mass |
| Q37328614 | Relation Between Hepatitis C Virus Exposure and Risk of Osteoporosis: A Nationwide Population-Based Study |
| Q46862781 | Selenoprotein P is the essential selenium transporter for bones |
| Q37266496 | Study of Hepatic Osteodystrophy in Patients with Chronic Liver Disease |
| Q35012136 | Vitamin D status and viral response to therapy in hepatitis C infected children |
Search more.